 CAPRISA 004 Phase IIb To compare 1% Tenofovir gel with a placebo gel is an expanded safety and effectiveness trial involving young women at risk of sexually transmitted HIV infection. While in the study, participants will be asked to apply a first dose of the assigned study gel within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. (South Africa)
March 2010
 iPrEx Phase III To determine whether daily use of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) can prevent HIV infection in men who also receive HIV counseling, condoms, and treatment for other sexually transmitted infections (STIs). (Brazil, Ecuador, Peru, South Africa, Thailand, United States)
July 2010
|
|
 MTN 003 (VOICE) Phase IIb To compare the safety and efficacy of oral versus topical pre-exposure prophylaxis (PrEP) for prevention of sexual transmission of HIV (Malawi, South Africa, Uganda, Zimbabwe)
August 2012
FEM-PREP Phase III To investigate the safety and effectiveness of a once-daily Truvada® pill (compared with placebo) in preventing HIV among HIV-uninfected women at risk of becoming infected through sexual intercourse. (Kenya, South Africa, Tanzania, United Republic of)
August 2012
Partners PrEP Phase III To see whether having PrEP in the bloodstream prevents the HIV uninfected partner from getting HIV. (Kenya, Uganda)
December 2012
CDC 4370 (Bangkok Tenofovir Study) Phase III, II The primary goals of this study are to assess the safety and efficacy of daily tenofovir to prevent parenteral HIV infection among injection drug users (IDUs). Assessment of changes in HIV associated risk behaviors, adherence to study drug, and, among IDU who become HIV-infected during the trial, evaluation of HIV viral load set point, CD4 counts, genetic characterization of infecting HIV viruses, and antiretroviral resistance will also be done. (Thailand)
December 2012
|
|
FACTS 001 Phase III To assess the safety and effectiveness of intravaginal 1% tenofovir gel in prevention HIV-1 injection and HSV-2 infection in sexually active young women. (South Africa)
December 2014
MTN 020 (ASPIRE) Phase III To assess safety and efficacy of the dapivirine ring. (Malawi, South Africa, Uganda, Zambia, Zimbabwe)
December 2014
 SILCS Diaphragm Plus TFV Phase III, II, I To look at use of the SILCS diaphragm and TFV. ()
December 2014
|
CAPRISA 008 Phase III To provide post-trial access for HIV negative CAPRISA 004 study participants to tenofovir gel; to develop and assess an implementation model for tenofovir gel provision through family planning services; and, to collect additional data on gel safety. (South Africa)
February 2015
 HPTN 052 Phase III Aims to assess immediate vs. delayed ART in HIV serodiscordant couples where the HIV infected individual has a CD4 cell count of 350 – 550 cells/mm. Delayed arm participants receive ART when their CD4 cell count falls below 250 cells/mm3 or they develop an AIDS-defining illness. (Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand, United States)
April 2015
 HVTN 505 Phase IIb To determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men. (United States)
April 2015
IPM 027 (The Ring Study) Phase III Phase II trial (with planned continuation as Phase III) to collect long-term safety and efficacy data on a long-acting dapivirine vaginal ring, replaced every four weeks. (Rwanda, South Africa)
August 2015
ANRS IPERGAY Phase III To evaluate a strategy for the prevention of HIV infection including "on demand" antiretroviral pre-exposure with Truvada versus placebo, associated with overall prevention (counselling, condoms, STD screening, HBV and HAV vaccinations and post-exposure treatment of HIV infection) in men who have sex with men (MSM), exposed to the risk of HIV infection. (Canada, France)
December 2016
|